Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
6.38
Dollar change
+0.14
Percentage change
2.24
%
Index- P/E- EPS (ttm)-1.20 Insider Own15.01% Shs Outstand174.10M Perf Week2.08%
Market Cap1.11B Forward P/E- EPS next Y-0.43 Insider Trans0.00% Shs Float147.97M Perf Month7.59%
Income-208.38M PEG- EPS next Q-0.10 Inst Own60.91% Short Float2.13% Perf Quarter-3.77%
Sales1.70M P/S653.39 EPS this Y43.13% Inst Trans-2.10% Short Ratio1.89 Perf Half Y175.00%
Book/sh0.64 P/B9.96 EPS next Y37.56% ROA-48.14% Short Interest3.15M Perf Year264.57%
Cash/sh1.38 P/C4.62 EPS next 5Y- ROE-101.61% 52W Range1.61 - 7.45 Perf YTD-0.93%
Dividend Est.5.00 (78.37%) P/FCF- EPS past 5Y3.32% ROI-63.09% 52W High-14.36% Beta1.89
Dividend TTM- Quick Ratio6.11 Sales past 5Y152.23% Gross Margin-286.63% 52W Low296.27% ATR (14)0.37
Dividend Ex-Date- Current Ratio6.11 EPS Y/Y TTM23.64% Oper. Margin-10337.34% RSI (14)56.06 Volatility4.64% 6.44%
Employees463 Debt/Eq2.01 Sales Y/Y TTM-72.59% Profit Margin-12272.26% Recom1.36 Target Price10.29
Option/ShortYes / Yes LT Debt/Eq1.96 EPS Q/Q-92.78% Payout- Rel Volume0.42 Prev Close6.24
Sales Surprise-100.00% EPS Surprise-68.25% Sales Q/Q-100.00% EarningsMar 14 BMO Avg Volume1.67M Price6.38
SMA207.64% SMA504.20% SMA20053.45% Trades Volume695,027 Change2.24%
Date Action Analyst Rating Change Price Target Change
Nov-09-23Initiated Deutsche Bank Buy $10
Mar-27-23Resumed Wells Fargo Overweight $8
Mar-17-23Initiated Bryan Garnier Buy $5
Jun-14-21Upgrade Jefferies Hold → Buy $6 → $12
Jan-29-21Downgrade JP Morgan Overweight → Neutral $9
Dec-28-20Resumed H.C. Wainwright Buy $19
Jul-31-20Initiated JP Morgan Overweight
Jul-22-20Initiated SunTrust Buy $38
Apr-22-20Initiated Mizuho Buy $18
Sep-23-19Initiated Needham Buy $26
Mar-21-24 01:43AM
Mar-17-24 09:19AM
Mar-15-24 05:53AM
Mar-14-24 01:51PM
07:00AM
07:00AM Loading…
Mar-12-24 07:00AM
Mar-11-24 07:00AM
Mar-09-24 01:09PM
Feb-29-24 07:00AM
Feb-22-24 07:00AM
Feb-12-24 02:29AM
Feb-08-24 07:00AM
06:07AM
05:45AM
Jan-23-24 07:00AM
07:00AM Loading…
Jan-22-24 07:00AM
Jan-10-24 07:00AM
Dec-22-23 07:00AM
Dec-18-23 02:58PM
Dec-09-23 08:30PM
Nov-27-23 07:00AM
Nov-15-23 07:00AM
Nov-06-23 07:00AM
Nov-05-23 05:34PM
Nov-02-23 09:00AM
07:11AM
Oct-17-23 07:00AM
Oct-11-23 08:07AM
07:00AM
Sep-05-23 07:00AM
04:32PM Loading…
Aug-07-23 04:32PM
Aug-04-23 06:29AM
Aug-03-23 07:00AM
Jul-19-23 07:00AM
Jul-18-23 07:00AM
Jul-06-23 07:00AM
Jun-27-23 07:00AM
Jun-20-23 07:00AM
Jun-16-23 07:00AM
Jun-14-23 09:39AM
Jun-06-23 07:00AM
Jun-04-23 07:11AM
Jun-02-23 07:00AM
May-22-23 07:00AM
May-12-23 07:00AM
May-04-23 07:00AM
May-01-23 10:15AM
Apr-27-23 07:01AM
07:00AM
Apr-26-23 04:01PM
07:06AM
Apr-25-23 07:00AM
Apr-20-23 07:00AM
Apr-16-23 09:30AM
Apr-14-23 11:08AM
Apr-04-23 07:00AM
Mar-14-23 07:00AM
Mar-13-23 07:00AM
Mar-08-23 10:45PM
03:22AM
Mar-07-23 07:00AM
Feb-28-23 09:40AM
Feb-15-23 07:00AM
Feb-08-23 11:05AM
Jan-24-23 09:40AM
Jan-23-23 05:49AM
Jan-20-23 07:00AM
Jan-09-23 07:00AM
Dec-26-22 12:35PM
Dec-21-22 04:01PM
Dec-12-22 10:00AM
Dec-09-22 11:31AM
07:43AM
Dec-08-22 09:11PM
04:03PM
04:02PM
04:01PM
Nov-30-22 07:00AM
Nov-29-22 11:35AM
Nov-09-22 05:16AM
Nov-05-22 08:35AM
Nov-03-22 09:31AM
07:00AM
Oct-21-22 07:00AM
Oct-12-22 11:30AM
07:00AM
Oct-04-22 10:21AM
07:00AM
Sep-20-22 07:30AM
Aug-04-22 07:00AM
Jul-21-22 07:54AM
07:00AM
Jul-11-22 06:00AM
Jul-06-22 07:00AM
Jun-10-22 03:01AM
May-31-22 04:01PM
May-27-22 07:45AM
May-13-22 06:58AM
May-12-22 10:51AM
May-05-22 07:00AM
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.